Zealand Pharma A/S ZEAL
17.59 0.00 (+0.00%)
At closeSep 29, 2022, 4:00 PM EDT
17.47 Day range 18.07
52-week range unavailable
News
globenewswire.com Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results Press Release – No. 22 / 2026 Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results Copenhagen, Denmark, November 5, 2026 – Zealand Pharma A/S…
globenewswire.com Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 Press release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3…
benzinga.com Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced a multi-target strategic collaboration with Zealand Pharma A/S (NASDAQ:ZEAL), a biotechnology company transforming the future of…
globenewswire.com Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases…
globenewswire.com Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes Company announcement – No. 54 / 2026 Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes…
globenewswire.com Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) Company announcement No. 53 / 2026 Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026) Copenhagen, Denmark, October 5, 2026 – Zealand Pharma A/S…
globenewswire.com Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts Press release – No. 19 / 2026 Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a…
globenewswire.com Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in…
globenewswire.com Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Company announcement – No. 51 / 2026 Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (“Zealand Pharma”…
globenewswire.com Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology Press release – No. 18 / 2026 Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes &…
globenewswire.com Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Company announcement No. 50 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or…
globenewswire.com Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity Press release – No. 17 / 2026 Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity The Phase 3 initiation marks a…
globenewswire.com Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Company announcement No. 49 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or…
globenewswire.com Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome Press release – No. 16 / 2026 Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome The CHMP of the European Medicines Agency has…
businesswire.com Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes DOVER, Del.--(BUSINESS WIRE)---- $ZEAL #BetaCells--Elvinix secures exclusive license to Zealand Pharma's GLP-1/gastrin dual-agonist peptides to develop a regenerative therapy for type 1 diabetes.
globenewswire.com Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Company announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or…
globenewswire.com Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 47 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 10, 2026 – Zealand Pharma A/S (“Zealand…
globenewswire.com Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference Press release – No. 15 / 2026 Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference Copenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL)…
globenewswire.com Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or…
globenewswire.com Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Company announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S ("the…
globenewswire.com Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Company announcement No. 44 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, August 31, 2026 – Zealand Pharma A/S ("the Company" or “Zealand…
globenewswire.com Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 43 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons…
benzinga.com Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
benzinga.com Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 198 companies reached new 52-week lows.
benzinga.com Earnings Scheduled For May 12, 2022 Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.
benzinga.com Earnings Scheduled For March 10, 2022 Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 524 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 368 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
benzinga.com Earnings Scheduled For November 11, 2021 Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.- benzinga.com Earnings Scheduled For August 12, 2021 Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
benzinga.com Earnings Scheduled For May 12, 2021 Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for its first quarter.- benzinga.com Earnings Scheduled For November 12, 2020 Companies Reporting Before The Bell • Redhill Biopharma (NASDAQ:RDHL) is projected to report quarterly loss at $0.16 per share on revenue of $25.37 million. • Alithya Group (NASDAQ:ALYA) is expected…
- benzinga.com 40 Stocks Moving in Tuesday's Pre-Market Session Gainers
- benzinga.com 62 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Highs On Friday
- benzinga.com Stocks That Hit 52-Week Highs On Thursday
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 60 Biggest Movers From Yesterday
- benzinga.com 44 Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket